Immtech Completes Malaria Prevention Trial

Immtech Pharmaceuticals, Inc. (Amex: IMM) announced that it has completed its first malaria prevention (or “malaria challenge”) trial of pafuramidine, Immtech’s oral drug candidate. The exploratory study was designed to determine whether the Company should focus on commercializing a blood-stage or a liver-stage malaria prevention drug. [click link for full article]

More: continued here

Filed under: Clinical Trials on November 4th, 2007